Usefulness of an Original Metabolic Syndrome Score in Large Intestinal Cancer Screening

Abstract

Background and Aims : Recently, it was reported that metabolic syndrome (MS) is related to the large intestinal neoplasm. Therefore, we studied the relationship between MS and the colonic neoplasm using our original scoring system, i.e., the Gastrointestinal Metabolic Syndrome Score (GIMS). Patients and Methods : The participants were medical examinees who underwent total colonoscopy (CS) from January to December 2006. Regarding body mass index, blood pressure, triglyceride, high density lipoprotein cholesterol and fasting blood sugar results in each case, we referred to the criteria of MS and scored them from 0-2 (0 : normal range, 1 : aberration minor, 2 : aberration). We added up the values to calculate the GIMS. We defined neoplastic lesions as adenoma or adenocarcinoma. When we found a neoplastic lesion in CS, we examined the case using the GIMS. Results : The average of GIMS in the neoplastic cases was significantly higher than that of the non-neoplastic cases (p<0.05). Considering the higher rate in the efficiency and in the therapeutic patients, we decided that the positive standard was two or more scores in GIMS. Conclusions : GIMS is easily calculated and can be used to support diagnosis of large intestinal neoplasm in the future.